# Moderna, Inc. (MRNA) — InvestMoat Analysis _Last analyzed: August 19, 2026_ _Asset class: equity · Canonical page: https://investmoat.com/stocks/mrna_ ## Scores | Dimension | Score (0–100) | | --- | --- | | Moat durability | 65 | | Growth trajectory | 73 | | Valuation | 59 | | **Composite** | **64** | | **Recommendation** | **Speculative Buy** | Scores are computed deterministically from this asset’s data by the InvestMoat formula (see https://investmoat.com/llms.txt for methodology). Scores are not directly comparable across asset classes. ## Key stats - **Ticker:** MRNA - **Market Cap:** ~$70B ## Moat Moderna's moat is an mRNA design-and-manufacture platform that just produced the first positive Phase 3 individualized neoantigen cancer therapy — intismeran autogene, 50/50 with Merck — sitting on top of a still-resetting respiratory vaccine franchise. The platform is real and now clinically validated in adjuvant melanoma; it is not a patent fortress, and COVID IP was just settled for $950 million. ### The mRNA Platform, Now with a Phase 3 Oncology Proof The competitive position rests on **individualized neoantigen manufacturing plus a 50/50 Merck oncology collaboration**, not on COVID vaccine share which has already collapsed: - **Intismeran: first Phase 3 mRNA cancer therapy:** On August 19, 2026 Merck and Moderna reported that INTerpath-001 (1,137 patients, 2:1, resected stage IIB–IV melanoma) met recurrence-free survival and distant metastasis-free survival at a pre-specified interim versus KEYTRUDA alone — the first Phase 3 win for an individualized neoantigen therapy and the first to show a clinically meaningful improvement over KEYTRUDA monotherapy in adjuvant melanoma. Hazard ratios were not disclosed; full data go to a medical meeting and to regulators. Five-year Phase 2b (KEYNOTE-942) showed a 49% cut in recurrence or death (HR 0.51) and a 59% cut in distant metastasis or death (HR 0.411). Nine Phase 2/3 INTerpath trials are underway across melanoma, NSCLC, bladder cancer and renal cell carcinoma; adjuvant RCC Phase 2 is fully enrolled and may be the next readout. - **Personalized manufacturing, 50/50 with Merck:** Each intismeran dose is built from a patient's tumor mutational signature — synthetic mRNA coding for up to 34 neoantigens inside Moderna's LNP. That workflow (sequencing → design → GMP batch per patient) is the switching cost, and it is also the scale risk: commercial adjuvant melanoma would require industrializing one-lot-per-patient manufacturing. Merck paid $250 million in 2022 to exercise its option; costs and profits are shared equally worldwide. Moderna does not own the oncology P&L outright, but it keeps the manufacturing node and the platform IP. - **Respiratory franchise after the COVID cliff:** FY2025 revenue was $1.9 billion after the pandemic unwind. Spikevax, mNEXSPIKE and mRESVIA remain the cash products; mFLUSIVA (mRNA-1010) won FDA approval on August 5, 2026 for adults 50+ (traditional 50–64, accelerated 65+) for the 2026–27 season, and mCOMBRIAX (flu+COVID) is authorized in the EU. 2026 guidance is up to +10% growth, ~50/50 US/international, with ~55% of H2 recognized in Q3. Norovirus (mRNA-1403) missed early-success criteria at the Phase 3 interim and needs another cohort. The respiratory book funds the oncology build; it is not a growth engine on the scale of 2021–22. - **IP settlement and remaining legal drag:** H1 2026 cost of sales included $884 million of royalties tied to a $950 million Arbutus/Genevant settlement paid in July. That cleared the largest LNP-patent overhang but left potential additional exposure of up to $1.3 billion and other ongoing litigation. Regulatory lock-in on approved vaccines is real; the COVID IP estate is no longer a free option. **Moat verdict:** Moderna is a net beneficiary of AI in the narrow sense that sequence-to-neoantigen design and trial operations compress with better models — that strengthens the process, it does not create a new moat. The AI-resilient pillars that actually matter are regulatory approvals on the respiratory franchise and the still-unapproved but now Phase-3-positive oncology dataset; both are intact, not strong. Talent and process knowledge are contestable. The COVID IP settlement showed the vulnerable side: LNP patents were never exclusive. Durability in the AI era depends on converting intismeran into approved, guideline-embedded therapy, not on software-style switching costs. ## Growth The 3–5 year growth path is no longer a COVID-decline story. FY2025 printed $1.9B; 2026 is guided up to +10% (~$2.1B) on international partnerships and mNEXSPIKE, with mFLUSIVA adding from the 2026–27 flu season. Intismeran is still pre-revenue — a 2027 filing and 2027–28 approval is the base path after today's Phase 3 hit — but a melanoma launch plus even one additional INTerpath indication would make oncology the second franchise by 2029. Q2 revenue was $145M (flat YoY) with a $(782)M GAAP loss ($(1.97)/sh); H1 revenue of $534M (+114%) is a seasonal-base effect, not the run-rate. Opex is still being cut (R&D guided $2.9B, SG&A $1.0B) and year-end cash is guided $4.7–5.2B after the settlement. - **Revenue CAGR estimate:** 12-20% - **Primary type:** TAM expansion - **Margin trend:** stable - **Key risk (high):** If FDA requires mature overall survival before accepting an intismeran filing and INTerpath-001 OS is not ready by mid-2027, and the fully enrolled Phase 2 adjuvant RCC readout (possible by year-end 2026) fails to corroborate the melanoma signal, intismeran stays a single-indication option while cash burns toward the $4.7–5.2B year-end floor — collapsing the platform multiple now in the price. - **Drivers:** - Intismeran autogene (mRNA-4157 / V940) — INTerpath-001 Phase 3 hit RFS + DMFS (Aug 19); 9 P2/P3 trials; Merck 50/50; pre-revenue, filing talks next (accelerating) - mFLUSIVA + respiratory combos — FDA approved Aug 5 for adults 50+; 2026–27 US season launch; mCOMBRIAX EU-authorized; norovirus interim miss (accelerating) - COVID + RSV (Spikevax, mNEXSPIKE, mRESVIA) — Q2 product sales $94M; FY2026 up to +10% vs $1.9B, COVID-rate declines already in the guide (stable) - **Score derivation:** Base ~81 (12–20% CAGR, midpoint 16%) + 2.7 trajectory (intismeran and flu accelerating, respiratory stable) + 0 stable margins − 10 high residual risk (Phase 3 HRs unpublished, OS immature, other tumors unproven) ≈ 73. The COVID cliff is already in the $1.9B base, not double-counted in severity. ## Valuation At $174.38 the stock has nearly tripled from the $62.96 close before the INTerpath-001 release, taking market cap to ~$70B. That is ~33× the ~$2.1B 2026 revenue guide and prices a multi-indication oncology platform, not a melanoma-only launch. 12–24 month fair value after the spike settles is the $145 base: melanoma filing in 2027 with one additional INTerpath signal. Spot sits ~20% above that base, 28% of the way toward the $250 bull. Trailing EPS is negative ($(7.98)); P/E is not a useful multiple until profitability, which is still a 2028–29 question. | Multiple | Value | Note | | --- | --- | --- | | Trailing P/E (GAAP) | N/A | TTM EPS $(7.98); Q2 2026 GAAP EPS $(1.97) | | Forward P/E (NTM) | N/A | Still GAAP-unprofitable; 2026 framework is a $(2–3)B operating loss on ~$2.1B revenue | | PEG Ratio | N/A | No forward earnings denominator until the opex cut and oncology launch converge | | Price / Sales (NTM) | ~33× | ~$70B market cap / ~$2.1B FY2026 revenue (up to +10% on $1.9B FY2025) | | Price / FCF | N/A | H1 2026 operating cash outflow $1.16B; YE cash guided $4.7–5.2B after the $950M settlement | On current sales the stock is expensive: ~33× NTM revenue for a still-unprofitable vaccine company. The multiple is a platform claim, not a respiratory claim — pre-readout the same $2.1B book was valued at ~$25B (~12×). That re-rating is only earned if intismeran files on RFS/DMFS, melanoma launches in 2027–28, and at least one more tumor type corroborates. Until Phase 3 hazard ratios are public and OS matures, the $174 print is closer to the bull path than to a melanoma-only DCF. _(as of August 19, 2026)_ ## Price scenarios ### Bear — $85 FDA wants mature OS before filing, the RCC readout does not corroborate melanoma, and COVID vaccination rates keep falling — the platform multiple unwinds toward the pre-readout capitalization plus a modest Phase 3 premium. - Regulators decline to file on RFS/DMFS alone and INTerpath-001 overall survival is not mature by mid-2027, pushing any melanoma launch past 2028 - The fully enrolled Phase 2 adjuvant RCC study fails to show a KEYTRUDA-like additive benefit, cutting the multi-tumor read-through that today's move priced - FY2026 revenue misses the +10% guide as US COVID demand undershoots and mFLUSIVA's first season is formulary-constrained, with cash through the $4.7B low end of the year-end range ### Base — $145 Intismeran files on the Phase 3 melanoma package in 2027, mFLUSIVA contributes in the 2026–27 season, and one additional INTerpath indication (RCC or bladder) produces a supportive signal — enough to hold a diversified-platform multiple without assuming NSCLC is already won. - Merck and Moderna present INTerpath-001 HRs in line with the Phase 2b direction of effect and open FDA/EMA filing talks in 1H 2027 - FY2026 revenue lands near the +10% guide (~$2.1B) and mFLUSIVA is available for the 2026–27 US season in adults 50+ - Adjuvant RCC Phase 2 (fully enrolled) or muscle-invasive bladder Phase 2 prints a directional win by mid-2027, keeping the nine-trial program intact ### Bull — $250 Melanoma is approved on RFS/DMFS, a second tumor type hits a registrational bar, and the market treats intismeran as a multi-indication KEYTRUDA-combination franchise rather than a single-cancer vaccine. - FDA accepts an adjuvant-melanoma filing without waiting for mature OS, and a 2027–28 approval makes intismeran the first individualized neoantigen therapy on the market - A second INTerpath study (adjuvant RCC, which William Blair flagged as potentially registrational, or high-risk Stage 1 NSCLC) meets its primary endpoint, unlocking a multi-billion peak-sales path beyond melanoma - Personalized manufacturing scales without a capacity bottleneck, mFLUSIVA plus mCOMBRIAX lift the respiratory floor, and the cash-burn path to 2028 profitability becomes visible --- InvestMoat is an open-source research and education framework. Nothing here is financial advice. Past performance does not guarantee future results.